Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although chemotherapy remains widely used, regulatory approvals in recent years of Merck’s pembrolizumab, GSK’s dostarlimab, and AstraZeneca’s durvalumab have transformed the treatment landscape, particularly benefiting patients with dMMR/MSI-H tumors. Ongoing late-phase clinical trials are refining patient segmentation through label expansions and new therapies, including an immune checkpoint inhibitor, a first-in-class targeted therapy, and antibody-drug conjugates, with expected approvals in the advanced setting. These advancements will drive market growth and diversification over the 2023-2033 forecast period, while addressing unmet needs, particularly for patients with limited treatment options, such as the p53wt, NSMP, and pMMR/MSS subgroups.

Questions answered

• How are recent approvals of immune checkpoint inhibitors reshaping the treatment landscape for advanced endometrial carcinoma, and what impact will this have on drug-treatment rates over time?
• How will biomarker-driven therapies influence treatment decisions and expand drug-treatable patient populations?
• What emerging therapies are poised to enter the market, and what level of uptake and sales can be expected over the 2023-2033 forecast period?
• What are the key drivers and constraints shaping the endometrial carcinoma market, and how will treatment dynamics evolve across major markets?

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed and recurrent incidence of endometrial carcinoma by country, segmented by drug-treatable and drug-treated early, and advanced disease and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key endometrial carcinoma therapies through 2033, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.